Next-generation Mobi patch pump (Sigi technology)

Sigi was AMF Medical's legacy patch-pump platform, not the name Tandem now uses for a current launch candidate. The tubeless, semi-reusable design began at the Swiss startup and Tandem Diabetes Care acquired it with AMF in January 2023 for roughly $200 million plus milestone payments.⁶⁷ Tandem's current roadmap instead describes a future next-generation Mobi patch pump that leverages the acquired Sigi technology.³

Components. Unlike most patch pumps, where the whole unit is thrown away, the legacy Sigi design was semi-reusable and rechargeable: a durable, rechargeable pump body snapped onto a disposable skin pad, and insulin came in standard pre-filled, swappable cartridges holding about 160 units.⁶⁸ It was designed as an "Alternate Controller Enabled" pump, the architecture needed to receive dosing commands from a Bluetooth CGM and controller.⁶ Tandem has not disclosed which of those exact implementation details will carry into the Sigi-derived next-generation Mobi.

Automation evidence. The legacy Sigi prototype never demonstrated AID in a clinical cohort; its only registered first-in-human study ran open-loop and has no posted results.¹ Control-IQ results provide context for Tandem's broader platform, not achieved performance for the Sigi-derived roadmap product. In the pivotal six-month randomized trial in people aged 14–71, Control-IQ raised time in range (70–180 mg/dL) from 61% to 71% — an ~11 percentage-point gain over a sensor-augmented pump — cut time below 70 mg/dL by about 0.88 points, and lowered HbA1c by ~0.33 points, while running in closed-loop mode ~90% of the time.⁹ A separate trial in children aged 6–13 found a similar 11-point time-in-range improvement (53% to 67%).¹⁰

Automation level and exercise. Current Control-IQ is a hybrid closed loop: it automates background (basal) insulin and delivers automatic correction boluses when glucose is predicted to run high, but meals must still be announced with a carbohydrate entry. It includes a sleep mode for tighter overnight targets and an exercise activity mode that raises the target during activity to reduce lows.⁹¹¹ Tandem has not disclosed the final algorithm or settings for the Sigi-derived product. A genuinely unannounced-meal (fully closed-loop) algorithm — where you would not count carbs — is still earlier-stage; Tandem has guided to starting its pivotal trial in late 2026 in earnings remarks, while the roadmap page lists the programme without a launch date.³

Ages, indications, and access. The legacy Sigi prototype received FDA Breakthrough Device designation on 30 November 2021, which was not an approval or a commercial indication.⁶ No separately branded commercial Sigi product exists in any region, and Tandem has not announced an age indication for the Sigi-derived next-generation Mobi.

What's coming. Tandem's current roadmap no longer describes a standalone product launch branded “Sigi.” It names two distinct concepts: an extended-wear site that would turn the current Mobi into a tubeless patch device, and a later, further-miniaturized next-generation Mobi patch pump that leverages the technology acquired with Sigi.³ Tandem confirmed on 6 August that it submitted a 510(k) for the current Mobi's tubeless capability during Q2 2026,⁵ but that filing is not a clearance and is not a filing for the Sigi-derived next-generation pump.

Tandem also lists dual glucose-ketone sensor integration and fully closed-loop algorithm work, without a current public filing or launch date on its innovations page.³ Sigi-derived design ideas therefore survive inside a future Mobi roadmap, not as a separately timed commercial product.